Merck Sharp and Dohme Corporation v Wyeth LLC

In the case of Merck Sharp and Dohme Corporation v Wyeth LLC, the court was presented with issues arising from a dispute between two pharmaceutical companies over patent infringement claims. Merck Sharp & Dohme Corporation and Merck Sharp & Dohme (Australia) Pty Ltd (Merck) filed proceedings seeking the revocation of certain claims of Australian patents related to pneumococcal polysaccharide-protein conjugate compositions and novel formulations that stabilize and inhibit precipitation of immunogenic compositions. Wyeth, owned by Pfizer Inc, filed a cross-claim against Merck for threatened infringement of some of these patents by the proposed sale in Australia of a 15-valent pneumococcal polysaccharide-protein conjugate vaccine. The court was required to decide on several legal issues, including whether Wyeth should be granted leave to amend its cross-claim to include an additional allegation of infringement and whether the respondents should be excused from complying with certain notices to produce.

The court found that Wyeth was not entitled to leave to amend its cross-claim to include an additional allegation of infringement. However, the court did grant Wyeth leave to issue a Notice to Produce on the respondent, requiring production of documents related to the decision-making process for the initial cross-claim and subsequent amendment. The court also exercised its discretion to excuse the respondents from complying with certain notices to produce, taking into account the need to balance the interests of both parties and the importance of the documents in question. Finally, the court ordered the respondent to pay the applicants' costs of both the respondent's interlocutory application and the applicants' interlocutory application. The outcome of this case highlights the importance of careful consideration of patent infringement claims and the need for parties to provide adequate justification for any amendments to their claims.